Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer
EntreMed Teams with JSB-Partners to Expedite Partnering of its Aurora Kinase Program
August 26th, 2008
EntreMed, Inc. (NASDAQ:ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced that it has engaged JSB-Partners, a global life sciences advisor, to enhance business development and partnering activities for its lead Aurora A/angiogenesis kinase inhibitor, ENMD-2076. ENMD-2076 is a novel, orally-active, selective kinase inhibitor with potent activity against Aurora A and tyrosine kinases linked to the promotion of cancer and inflammatory diseases. ENMD-2076 has a unique combination of target activities including cell cycle inhibition (Aurora A), antiangiogenesis (VEGFR, FGFR, PDGFR), and...
Source: Cancer Weekly (2008-08-26)
|
